Back to top
CCRAN is grateful to our Steering Committee for bringing their knowledge and expertise to the development of the 2026 Biomarkers Conference.
Dr. Banerji is a Medical Oncologist at CancerCare Manitoba with a practice focused on lung cancer and sarcoma. He is also the Director of Precision Oncology and Advanced Therapeutics where he guides the strategy to implement companion diagnostics for cancer care. His laboratory at the Paul Albrechtsen Research Institute is focused on the application of Comprehensive Genomic Profiling to guide the cancer discovery and treatment.
Dr. Krzyzanowska is a Professor of Medicine at University of Toronto and a practicing GI medical oncologist at Sunnybrook. She is the Chief of the Odette Cancer Centre at Sunnybrook and the Regional Vice President, Cancer Services for the Toronto Central North region with Ontario Health – Cancer Care Ontario. Her research seeks to advance the science and practice of healthcare quality as it relates to the delivery of cancer care. Dr. Krzyzanowska obtained her medical degree and clinical training at the University of Toronto then completed a research fellowship at the Centre for Outcomes and Policy Research at the Dana Farber Cancer Institute and the Harvard School of Public Health.
Georgia Balsevich is the Senior Sector Innovation Manager, Health at Genome Alberta, a not-for-profit funding organization advancing genomics innovation in Alberta to drive economic and societal impact. In this role, Georgia oversees Genome Alberta’s health research portfolio and leads the development of funding programs that address community-identified health priorities through genomic approaches. Georgia has a postdoctoral background in genetics, with research focused on the complex interplay between genetic and environmental factors underlying complex diseases. She completed her Doctor of Philosophy (Ph.D.) at the Max Planck Institute of Psychiatry in Munich, Germany, her Master of Science (M.Sc.) at the University of British Columbia, and holds a Project Management Professional (PMP) certification from the Project Management Institute. At Genome Alberta, Georgia is committed to advancing patient care by enabling applied genomics research with real-world impact.
Matthew Brougham is a seasoned health economist and senior global consultant with expertise in health technology assessment, market access, and health policy. He serves as a Senior Global Consultant at Certara Evidence & Access and leads strategic consulting through Brougham Consulting Inc., advising public and private sector clients on value assessment for health technologies.
Before his current consulting roles, Matthew held several high-level leadership positions in national health agencies. Notably, he was Vice President of Products and Services at the Canadian Agency for Drugs and Technologies in Health (CADTH), where he played a central role in shaping evidence-based evaluation frameworks for drugs and medical technologies. He also served internationally as Chief Executive of PHARMAC, New Zealand’s government agency responsible for managing the national pharmaceutical schedule, giving him first-hand experience with market access and formulary decision-making in universal health systems.
Katie Hulan is a marketing professional and advocate for lung health. Diagnosed with Stage IV ALK Positive lung cancer at 33 years old, Katie's journey has taken her from living in Toronto to now Victoria, BC, offering her unique insights into provincial cancer care experiences. She uses her experience to better lung health and patient experiences across Canada, and is a board member of ALK Positive Canada. When she is not working or advocating, you’ll find her out hiking, exploring new areas and things to do, being part of her community, or spending time with friends and family.
Don Husereau is an Adjunct Professor of Medicine at The University of Ottawa. He does freelance health care research and works with private and public sector life sciences organizations to help them understand the value of health technology and its implications for health and innovation policy.
.png)
Dr. Itani received her Bachelor of Science Degree in Medical Laboratory Technology followed by her Doctor of Medicine Degree from the American University of Beirut. She is American Board Certified in Anatomical and Clinical Pathology with subspecialty specialization in Hematopathology and Molecular Genetics Pathology.
Dr. Itani started her practice at the Foothills Medical Center, Calgary, Alberta where she strived for exemplary clinical practice and pursued, in the form of self-study, another field of interests: Bone and Soft Tissue Pathology. Given her passion for translational research, she was appointed the “Liaison for Translational Research” allowing for multiple collaborations between pathologists, surgeons, oncologists, and basic science researchers.
Currently, Dr. Itani is an Associate Professor at Dalhousie University and the Head of the Division of Molecular Diagnostics and Cytogenetics Laboratory at Saint John Regional Hospital where she has introduced Comprehensive Genomic Profiling as a routine practice in clinical genetic tumor testing, the first in Canada. She continues to implement cutting edge technology such as Optical Genome Mapping providing advanced complex but essential clinical services to New Brunswick patients.
Dr. Manna is a medical oncologist at the Saskatoon Cancer Centre and Associate Professor in the Department of Oncology at the University of Saskatchewan. She is the Provincial Disease Site Lead and the Multidisciplinary Tumor Board Chair for Breast Malignancies. She is a nucleus member of the REAL Alliance, Canadian Breast Cancer Alliance. Her clinical focus includes breast and thoracic malignancies, with research interests in mainstream genetic testing, quality improvement, and real-world outcomes.
.png){kind=logo}
